Multi-Specific Engager Proteins with Diverse & Novel Functionalities

• Our Phase 1/2 clinical program solves critical issues confronting CAR-T cell therapies
• Our clinical development programs illustrate how the modularity inherent in our technology broadens the pipeline to solid tumors and AML
• Our unique costimulatory engagers provide an early look at the future of bispecific and multi-specific therapies

Speakers:

Paul Rennert

Acting Chief Executive Officer, President & Chief Scientific Officer

Aleta Biotherapeutics